- Home
- IMMP vs MFIN Comparison
IMMP vs MFIN Comparison
Compare IMMP & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- MFIN
- Stock Information
- Founded
- IMMP 1987
- MFIN 1995
- Country
- IMMP Australia
- MFIN United States
- Employees
- IMMP N/A
- MFIN N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- MFIN Finance: Consumer Services
- Sector
- IMMP Health Care
- MFIN Finance
- Exchange
- IMMP Nasdaq
- MFIN Nasdaq
- Market Cap
- IMMP 256.1M
- MFIN 243.9M
- IPO Year
- IMMP N/A
- MFIN 1996
- Fundamental
- Price
- IMMP $1.90
- MFIN $10.03
- Analyst Decision
- IMMP Buy
- MFIN Strong Buy
- Analyst Count
- IMMP 1
- MFIN 1
- Target Price
- IMMP $7.00
- MFIN $12.00
- AVG Volume (30 Days)
- IMMP 128.2K
- MFIN 43.7K
- Earning Date
- IMMP 02-22-2026
- MFIN 10-29-2025
- Dividend Yield
- IMMP N/A
- MFIN 4.79%
- EPS Growth
- IMMP N/A
- MFIN 1.06
- EPS
- IMMP N/A
- MFIN 1.71
- Revenue
- IMMP $3,306,742.00
- MFIN $338,783,000.00
- Revenue This Year
- IMMP N/A
- MFIN N/A
- Revenue Next Year
- IMMP N/A
- MFIN $3.82
- P/E Ratio
- IMMP N/A
- MFIN $5.87
- Revenue Growth
- IMMP 31.28
- MFIN 15.53
- 52 Week Low
- IMMP $1.32
- MFIN $7.71
- 52 Week High
- IMMP $2.71
- MFIN $10.98
- Technical
- Relative Strength Index (RSI)
- IMMP 56.87
- MFIN 55.04
- Support Level
- IMMP $1.68
- MFIN $9.14
- Resistance Level
- IMMP $1.95
- MFIN $9.65
- Average True Range (ATR)
- IMMP 0.09
- MFIN 0.32
- MACD
- IMMP 0.01
- MFIN 0.02
- Stochastic Oscillator
- IMMP 82.14
- MFIN 87.24
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.